• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用硫醇反应性底物鉴定人P-糖蛋白药物结合位点中的残基。

Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate.

作者信息

Loo T W, Clarke D M

机构信息

Medical Research Council Group in Membrane Biology, Departments of Medicine and Biochemistry, University of Toronto, Ontario M5S 1A8, Canada.

出版信息

J Biol Chem. 1997 Dec 19;272(51):31945-8. doi: 10.1074/jbc.272.51.31945.

DOI:10.1074/jbc.272.51.31945
PMID:9405384
Abstract

We identified a thiol-reactive compound, dibromobimane (dBBn), that was a potent stimulator (8.2-fold) of the ATPase activity of Cys-less P-glycoprotein. We then used this compound together with cysteine-scanning mutagenesis to identify residues in transmembrane segment (TM) 6 and TM12 that are important for function. TM6 and TM12 lie close to each other in the tertiary structure and are postulated to be important for drug-protein interactions. The majority of P-glycoprotein mutants containing a single cysteine residue retained substantial amounts of drug-stimulated ATPase activity and were not inhibited by dBBn. The ATPase activities of mutants L339C, A342C, L975C, V982C, and A985C, however, were markedly inhibited (>60%) by dBBn. The drug substrates verapamil, vinblastine, and colchicine protected these mutants against inhibition by dBBn, suggesting that these residues are important for interaction of substrates with P-glycoprotein. We previously showed that residues Leu339, Ala342, Leu975, Val982, and Ala985 lie along the point of contact between helices TM6 and TM12, when both are aligned in a left-handed coiled coil (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 20986-20989). Taken together, these results suggest that the interface between TM6 and TM12 likely forms part of the potential drug-binding pocket in P-glycoprotein.

摘要

我们鉴定出一种硫醇反应性化合物二溴双马来酰亚胺(dBBn),它是无半胱氨酸P-糖蛋白ATP酶活性的强效刺激剂(8.2倍)。然后我们将该化合物与半胱氨酸扫描诱变结合使用,以鉴定跨膜区段(TM)6和TM12中对功能重要的残基。TM6和TM12在三级结构中彼此靠近,据推测对药物-蛋白质相互作用很重要。大多数含有单个半胱氨酸残基的P-糖蛋白突变体保留了大量的药物刺激的ATP酶活性,并且不受dBBn抑制。然而,突变体L339C、A342C、L975C、V982C和A985C的ATP酶活性被dBBn显著抑制(>60%)。药物底物维拉帕米、长春碱和秋水仙碱可保护这些突变体免受dBBn抑制,这表明这些残基对于底物与P-糖蛋白的相互作用很重要。我们之前表明,当螺旋TM6和TM12以左手卷曲螺旋排列时,亮氨酸339、丙氨酸342、亮氨酸975、缬氨酸982和丙氨酸985沿着它们之间的接触点排列(Loo,T.W.,和Clarke,D.M.(1997)J.Biol.Chem.272,20986-20989)。综上所述,这些结果表明TM6和TM12之间的界面可能构成P-糖蛋白中潜在药物结合口袋的一部分。

相似文献

1
Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate.使用硫醇反应性底物鉴定人P-糖蛋白药物结合位点中的残基。
J Biol Chem. 1997 Dec 19;272(51):31945-8. doi: 10.1074/jbc.272.51.31945.
2
Identification of residues in the drug-binding domain of human P-glycoprotein. Analysis of transmembrane segment 11 by cysteine-scanning mutagenesis and inhibition by dibromobimane.人P-糖蛋白药物结合结构域中残基的鉴定。通过半胱氨酸扫描诱变分析跨膜片段11以及二溴双马来酰亚胺的抑制作用。
J Biol Chem. 1999 Dec 10;274(50):35388-92. doi: 10.1074/jbc.274.50.35388.
3
Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil.使用维拉帕米的甲硫基磺酸盐类似物MTS-维拉帕米确定人类多药耐药P-糖蛋白中的药物结合位点。
J Biol Chem. 2001 May 4;276(18):14972-9. doi: 10.1074/jbc.M100407200. Epub 2001 Feb 14.
4
Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane.通过半胱氨酸扫描诱变和与二溴双马来酰亚胺反应鉴定人类多药耐药性P-糖蛋白药物结合域内的残基。
J Biol Chem. 2000 Dec 15;275(50):39272-8. doi: 10.1074/jbc.M007741200.
5
Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates.药物底物对人P-糖蛋白预测跨膜片段(TM)6中第332位和预测TM12中第975位工程化半胱氨酸残基之间氧化交联的抑制作用。
J Biol Chem. 1996 Nov 1;271(44):27482-7. doi: 10.1074/jbc.271.44.27482.
6
Cross-linking of human multidrug resistance P-glycoprotein by the substrate, tris-(2-maleimidoethyl)amine, is altered by ATP hydrolysis. Evidence for rotation of a transmembrane helix.底物三(2-马来酰亚胺乙基)胺对人多药耐药性P-糖蛋白的交联作用会因ATP水解而改变。跨膜螺旋旋转的证据。
J Biol Chem. 2001 Aug 24;276(34):31800-5. doi: 10.1074/jbc.M103498200. Epub 2001 Jun 27.
7
Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein.两种不同药物同时结合于人多药耐药性P-糖蛋白的结合口袋中。
J Biol Chem. 2003 Oct 10;278(41):39706-10. doi: 10.1074/jbc.M308559200. Epub 2003 Aug 7.
8
Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein.若丹明结合位点在人类多药耐药P-糖蛋白中的位置。
J Biol Chem. 2002 Nov 15;277(46):44332-8. doi: 10.1074/jbc.M208433200. Epub 2002 Sep 9.
9
Drug-stimulated ATPase activity of human P-glycoprotein requires movement between transmembrane segments 6 and 12.药物刺激的人P-糖蛋白ATP酶活性需要跨膜片段6和12之间的移动。
J Biol Chem. 1997 Aug 22;272(34):20986-9. doi: 10.1074/jbc.272.34.20986.
10
Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein.位于预测的跨膜片段6(TM6)中的氨基酸突变可调节人P-糖蛋白的活性和底物特异性。
Biochemistry. 1994 Nov 29;33(47):14049-57. doi: 10.1021/bi00251a013.

引用本文的文献

1
Thioxobimanes.硫代双甲川类化合物
J Org Chem. 2023 Oct 6;88(19):13475-13489. doi: 10.1021/acs.joc.3c00873. Epub 2023 Sep 15.
2
The human proton pump inhibitors inhibit rifampicin efflux and macrophage-induced rifampicin tolerance.人质子泵抑制剂抑制利福平外排和巨噬细胞诱导的利福平耐受。
Proc Natl Acad Sci U S A. 2023 Feb 14;120(7):e2215512120. doi: 10.1073/pnas.2215512120. Epub 2023 Feb 10.
3
Target-Agnostic P-Glycoprotein Assessment Yields Strategies to Evade Efflux, Leading to a BRAF Inhibitor with Intracranial Efficacy.
靶向无关的 P-糖蛋白评估产生了逃避外排的策略,从而导致具有颅内疗效的 BRAF 抑制剂。
J Am Chem Soc. 2022 Jul 13;144(27):12367-12380. doi: 10.1021/jacs.2c03944. Epub 2022 Jun 27.
4
Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein.关于多药转运蛋白P-糖蛋白对多特异性底物识别机制的新共识。
Cancer Drug Resist. 2019 Sep 19;2(3):471-489. doi: 10.20517/cdr.2019.22. eCollection 2019.
5
Extended-ensemble docking to probe dynamic variation of ligand binding sites during large-scale structural changes of proteins.扩展系综对接以探究蛋白质大规模结构变化过程中配体结合位点的动态变化。
Chem Sci. 2022 Mar 16;13(14):4150-4169. doi: 10.1039/d2sc00841f. eCollection 2022 Apr 6.
6
Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).小分子转运蛋白系统被转运蛋白干扰化学品(TICs)破坏。
FEBS Lett. 2020 Dec;594(23):4158-4185. doi: 10.1002/1873-3468.14005. Epub 2020 Dec 9.
7
Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.人 P 糖蛋白(ABCB1)的同源建模及分子对接研究对配体结合的深入了解。
Int J Mol Sci. 2020 Jun 5;21(11):4058. doi: 10.3390/ijms21114058.
8
Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.格列替尼,一种c-MET/SMO双重抑制剂,可拮抗P-糖蛋白介导的癌细胞多药耐药性。
Front Oncol. 2019 Apr 25;9:313. doi: 10.3389/fonc.2019.00313. eCollection 2019.
9
An Energetically Favorable Ligand Entrance Gate of a Multidrug Transporter Revealed by Partial Nudged Elastic Band Simulations.通过部分微扰弹性带模拟揭示的多药转运蛋白的能量有利配体入口门
Comput Struct Biotechnol J. 2019 Feb 22;17:319-323. doi: 10.1016/j.csbj.2019.02.008. eCollection 2019.
10
Evidence for the critical role of transmembrane helices 1 and 7 in substrate transport by human P-glycoprotein (ABCB1).人 P-糖蛋白(ABCB1)跨膜螺旋 1 和 7 在底物转运中的关键作用的证据。
PLoS One. 2018 Sep 28;13(9):e0204693. doi: 10.1371/journal.pone.0204693. eCollection 2018.